Gerald Chu

1.4k total citations · 1 hit paper
14 papers, 1.1k citations indexed

About

Gerald Chu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gerald Chu has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gerald Chu's work include CAR-T cell therapy research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Prostate Cancer Treatment and Research (3 papers). Gerald Chu is often cited by papers focused on CAR-T cell therapy research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Prostate Cancer Treatment and Research (3 papers). Gerald Chu collaborates with scholars based in United States, Netherlands and Belgium. Gerald Chu's co-authors include Zhihu Ding, Ronald A. DePinho, Ramya Kollipara, D. Gary Gilliland, Shan Jiang, James W. Horner, Zuzana Tóthová, Diego H. Castrillón, Yonghong Xiao and Lili Miao and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Blood.

In The Last Decade

Gerald Chu

12 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis

2007 859 citations Ji-Hye Paik, Ramya Kollipara et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerald Chu United States	5	924	234	195	165	153	14	1.1k
Kelly S. Clark United States	5	482 0.5×	209 0.9×	134 0.7×	48 0.3×	144 0.9×	7	758
Stefania Zona United Kingdom	16	918 1.0×	285 1.2×	182 0.9×	33 0.2×	75 0.5×	17	1.1k
Ka-Kei Ho United Kingdom	8	595 0.6×	172 0.7×	288 1.5×	40 0.2×	87 0.6×	8	978
Sean Garrison United States	10	595 0.6×	354 1.5×	142 0.7×	12 0.1×	135 0.9×	13	970
Paula Gutierrez‐Martinez Spain	10	763 0.8×	360 1.5×	138 0.7×	23 0.1×	67 0.4×	12	1.0k
Ilaria Guccini Switzerland	12	468 0.5×	315 1.3×	123 0.6×	47 0.3×	371 2.4×	15	1000
Stéphanie Courtois-Cox France	5	655 0.7×	336 1.4×	167 0.9×	41 0.2×	117 0.8×	5	930
Qihao Ren United States	8	457 0.5×	247 1.1×	129 0.7×	37 0.2×	259 1.7×	12	875
Joachim Theilhaber United States	11	406 0.4×	154 0.7×	50 0.3×	18 0.1×	84 0.5×	18	634
Mitchell E. Fane United States	14	556 0.6×	419 1.8×	183 0.9×	23 0.1×	276 1.8×	23	1.1k

Countries citing papers authored by Gerald Chu

Since Specialization

Citations

This map shows the geographic impact of Gerald Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Chu more than expected).

Fields of papers citing papers by Gerald Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Chu. The network helps show where Gerald Chu may publish in the future.

Co-authorship network of co-authors of Gerald Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Chu. A scholar is included among the top collaborators of Gerald Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Chu. Gerald Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Shen, Fei, Krista Menard, Shaozhou K. Tian, et al.. (2025). Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer. Clinical Cancer Research. 31(21). 4543–4556.

Shen, Fei, William Kevin Kelly, Neeta Pandit‐Taskar, et al.. (2024). Preclinical characterization of human Kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). 202–202. 2 indexed citations

Ma, Xuewen, Gary Borzillo, Gerald Chu, et al.. (2023). A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants. Clinical Pharmacology & Therapeutics. 115(5). 1075–1084.

Tepper, Armand W.J.W., et al.. (2022). Development and characterization of rabbit monoclonal antibodies that recognize human spermine oxidase and application to immunohistochemistry of human cancer tissues. PLoS ONE. 17(4). e0267046–e0267046. 4 indexed citations

Basu, Subhasree, Mike R. Russell, Katrin Sproesser, et al.. (2022). Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models. Cancer Research. 82(12_Supplement). LB087–LB087. 1 indexed citations

Diem, Michael, Weirong Wang, Robert Schulingkamp, et al.. (2020). Abstract 5662: JNJ-67571244: A novel anti-CD33 C2 domain binding bispecific antibody with potent T cell redirection activity. Cancer Research. 80(16_Supplement). 5662–5662. 1 indexed citations

Smith, Melissa, Diana Chin, Szeman Ruby Chan, et al.. (2020). Abstract 5567: In vivo administration of the STING agonist, JNJ-67544412, leads to complete regression of established murine subcutaneous tumors. Cancer Research. 80(16_Supplement). 5567–5567. 9 indexed citations

Diem, Michael, Weirong Wang, Robert Schulingkamp, et al.. (2020). A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Advances. 4(5). 906–919. 35 indexed citations

Pillarisetti, Kodandaram, Suzanne C. Edavettal, Mark Mendonça, et al.. (2020). A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 135(15). 1232–1243. 115 indexed citations

10.

Damle, Rajendra N., David C. DeRosa, Anna C. Hughes, et al.. (2019). Abstract 2134: Niraparib combined with abiraterone acetate inhibits the growth of BRCA2wt prostate tumors. Cancer Research. 79(13_Supplement). 2134–2134. 1 indexed citations

11.

Menard, Krista, Emily Chen, Kristen Chevalier, et al.. (2018). Abstract A11: Preclinical assessment of CD3 bispecific antibody efficacy: A comparison of humanized mouse models bearing xenografts and syngeneic mouse models using surrogate antibodies. Cancer Research. 78(10_Supplement). A11–A11. 1 indexed citations

12.

Chu, Gerald, et al.. (2014). Abstract A15: Development of a cloud-based histology database for collaborative cancer research. Molecular Cancer Research. 12(11_Supplement). A15–A15. 1 indexed citations

13.

Gan, Boyi, Carol S. Lim, Gerald Chu, et al.. (2010). FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis. Cancer Cell. 18(5). 472–484. 116 indexed citations

14.

Paik, Ji-Hye, Ramya Kollipara, Gerald Chu, et al.. (2007). FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis. Cell. 128(2). 309–323. 859 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact